BIIB

#462
Biogen Inc. - Common Stock
195.9 1 USD
-0.79%
부문: 헬스케어
베이스: USD
수익 통화: USD
일일 변동 비율
195.55
198.00
년간 변동
121.06
205.97
일일 변동
-0.79%
월간 변동
+0.96%
6달 변화
+8.75%
년간 변동율
+48.63%
이전 종가
197.4 7
Open
195.5 5
저가
195.5 5
High
198.0 0
양
73
전체 차트 열기 Full chart

Financials

개요 성명 통계
4분기 연간
  • Market Capitalization 28.92 B
  • Employee 7 500
  • Founded 1978
  • CEO Chris Viehbacher
  • Website www.biogen.com
  • Headquarter Delaware, United States
  • FIGI BBG000C17X76
  • Industry 종합 의약품 제조업체
총매출
순이익
주당 순이익(기본 EPS)
총부채
잉여 현금 흐름
현금 및 현금성 자산
주가수익비율
20.02
주가매출액비율
2.62

Biogen Inc. - Common Stock

Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate, diroximel fumarate, interferon beta-1a, peginterferon beta-1a, and natalizumab, all for the treatment of multiple sclerosis; nusinersen for the treatment of spinal muscular atrophy; omaveloxolone for the treatment of Friedreich's ataxia; tofersen for the treatment of ALS; and dimethyl fumarate for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs. The company is ranked 424th on the Fortune 500 and 845th on the Forbes Global 2000.

뉴스